These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35839531)

  • 1. Accelerating drug development in breast cancer: New frontiers for ER inhibition.
    Ferraro E; Walsh EM; Tao JJ; Chandarlapaty S; Jhaveri K
    Cancer Treat Rev; 2022 Sep; 109():102432. PubMed ID: 35839531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
    Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
    J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer.
    Li CL; Moi SH; Lin HS; Hou MF; Chen FM; Shih SL; Kan JY; Kao CN; Wu YC; Kao LC; Chen YH; Lee YC; Chiang CP
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
    Bhatia N; Hazra S; Thareja S
    Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
    Saha T; Makar S; Swetha R; Gutti G; Singh SK
    Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer.
    Haines CN; Wardell SE; McDonnell DP
    Essays Biochem; 2021 Dec; 65(6):985-1001. PubMed ID: 34328178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y; Liu W
    J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-aromatase and anti-estrogenic activity of plant products in the treatment of estrogen receptor-positive breast cancer.
    Verhoog NJD; Spies LL
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106581. PubMed ID: 38997071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
    Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y; Tang SC
    Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.
    Saatci O; Huynh-Dam KT; Sahin O
    J Mol Med (Berl); 2021 Dec; 99(12):1691-1710. PubMed ID: 34623477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New steps on an old path: Novel estrogen receptor inhibitors in breast cancer.
    Pagliuca M; Donato M; D'Amato AL; Rosanova M; Russo AOM; Scafetta R; De Angelis C; Trivedi MV; André F; Arpino G; Del Mastro L; De Laurentiis M; Puglisi F; Giuliano M
    Crit Rev Oncol Hematol; 2022 Dec; 180():103861. PubMed ID: 36374739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
    Hernando C; Ortega-Morillo B; Tapia M; Moragón S; Martínez MT; Eroles P; Garrido-Cano I; Adam-Artigues A; Lluch A; Bermejo B; Cejalvo JM
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
    Cleator SJ; Ahamed E; Coombes RC; Palmieri C
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
    Scott JS; Barlaam B
    Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.